Abstracts Archive - Page 1866 of 2607 - ACR Meeting Abstracts

Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 3186 • 2015 ACR/ARHP Annual Meeting
Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes
Mihir D. Wechalekar^1,2,3, Susan Lester^4,5, Maureen Rischmueller^6,7, Catherine Hill^8,9 and Susanna Proudman^1,8, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²School of Medicine, Flinders University School of Medicine, Adelaide, Australia, ³Repatriation General Hospital, Rheumatology Research Unit, Daw Park, Australia, ⁴Rheumatology, Basil Hetzel Institute, QEH, Woodville South, Australia, ⁵Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁶Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ⁷University of Adelaide, Adelaide, Australia, ⁸Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁹The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
Background/Purpose: Previous cross-sectional data revealed disease activity (DA) measures that omit foot joint assessment inadequately capture foot synovitis in in apparent remission at 6 months1.…
Abstract Number: 3187 • 2015 ACR/ARHP Annual Meeting
Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population
Bindee Kuriya¹, Xiuying Li², George A. Tomlinson³, Edward C. Keystone⁴, Claire Bombardier² and OBRI Investigators, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The timing and severity of relapse and likelihood of “recapturing” remission following a relapse in RA is not well known. We aimed to describe…
Abstract Number: 3188 • 2015 ACR/ARHP Annual Meeting
Inhibition of Lymphatic Muscle Contraction By Lymphatic Endothelial iNOS Impairs Lymph Drainage from Arthritic Joints in TNF-Tg Mice and Is Prevented By Herbal Drugs
Qianqian Liang¹, Yan Chen¹, Jinlong Li¹, Wensheng Wang², Li Zhang¹, Hao Xu¹, Ronald Wood², Brendan Boyce², Edward Schwarz³, Yongjun Wang¹ and Lianping Xing⁴, ¹Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ²University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Rochester, NY
Background/Purpose: We reported previously that inflammation in TNF-Tg mice, a model of rheumatoid arthritis (RA), inhibits lymphatic vessel maturation, resulting in decreased lymphatic smooth muscle…
Abstract Number: 3189 • 2015 ACR/ARHP Annual Meeting
Enhancement of Mitochondrial Biogenesis Inhibits Cell Proliferation and MMP-3/RANKL Secretion in Rheumatoid Arthritis Fibroblast-like Synovial Cells and Joint Destruction in Arthritis Model Mice
Takeshi Ueha¹, Yoshitada Sakai¹, Masayuki Morishita², Toshihisa Maeda², Koji Fukuda², Miho Inoue², Risa Harada², Masaya Minoda², Yasushi Miura^3,4,5, Akira Hashiramoto⁶ and Masahiro Kurosaka^1,4, ¹Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Orthpaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ⁶Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Joint destruction in rheumatoid arthritis (RA) progresses via the hyperproliferation of the synovium and secretion of MMP-3/RANKL from fibroblast-like synoviocytes (FLS). In tumors, we previously…
Abstract Number: 3190 • 2015 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Aranzazu Mediero¹, Tuere Wilder² and Bruce Cronstein³, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of the joints and some extra-articular tissues. Netrin-1 is a laminin-like…
Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting
Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Takuya Matsumoto¹, Nobunori Takahashi¹, Toshihisa Kojima¹ and Naoki Ishiguro², ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
Abstract Number: 3192 • 2015 ACR/ARHP Annual Meeting
KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA
Siba Raychaudhuri¹, Smriti K. Raychaudhuri² and Heike Wulff³, ¹Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA, ³Pharmacology, UC Davis School of Medicine, Davis, CA
Background/Purpose: KCa3.1 is a Ca2+-activated K+ channel that modulates Ca2+-dependent signaling processes such as activation and cellular proliferation. KCa3.1 is expressed in CCR7+ naïve and…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 3194 • 2015 ACR/ARHP Annual Meeting
Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Michael Schiff¹ and Peter Sadowski², ¹Division of Rheumatology, University of Colorado, Denver, CO, ²Antares Pharma Inc., Minneapolis, MN
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy1 but absorption saturation limitations compromise oral MTX bioavailability (BA). Subcutaneous (SC) MTX has a…
Abstract Number: 3195 • 2015 ACR/ARHP Annual Meeting
Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial
Jacob Sode^1,2,3, Sophine B. Krintel⁴, Anting L. Carlsen⁵, Merete Lund Hetland⁶, Julia Johansen^7,8, Kim Hørslev-Petersen⁹, Kristian Stengaard-Pedersen¹⁰, Peter Junker¹¹, Mikkel Østergaard^12,13, Niels H. H. Heegaard^14,15 and OPERA study group, ¹Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ²Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ⁶The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁷Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁸Departments of Medicine and Oncology, Copenhagen University Hospital at Herlev, Copenhagen, Denmark, ⁹Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark, ¹⁰Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹²Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ¹³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ¹⁴Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ¹⁵Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose: The variable response to anti-TNF therapy in patients with rheumatoid arthritis (RA) remains largely unexplained, and biomarkers for treatment response are scarce. We previously…
Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁵Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Ernest H. Choy¹, Corrado Bernasconi², Maher Aassi², Jose F. Molina³ and Oscar M. Epis⁴, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Centro Integral de Reumatologia Reumalab, Medellin, Colombia, ⁴Rheumatology Unit, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
Abstract Number: 3199 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
julien henry¹, stéphane pavy², Jacques Gottenberg³, rakiba belkhir⁴, Stéphanie Rouanet⁵, Jérémie Sellam⁶, Xavier Mariette⁷ and raphaèle seror⁴, ¹departement of rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ²rheumatology, Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ³Hautepierre, Strasbourg, France, ⁴Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁵Biostatistics, Roche France, Boulogne-Billancourt, France, ⁶Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ⁷Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: In RA patients, different randomized clinical trials have showed that the efficacy of reduced dose of RTX either initially and for subsequent courses (DANCER,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].